The Present and Future of Vagus Nerve Stimulation

Jeyul Yang, M.D., Ji Hoon Phi, M.D., Ph.D.
Division of Pediatric Neurosurgery, Seoul National University Children’s Hospital, Seoul, Korea

Epilepsy is one of the major chronic neurological diseases affecting many patients. Resection surgery is the most effective therapy for medically intractable epilepsy, but it is not feasible in all patients. Vagus nerve stimulation (VNS) is an adjunctive neuromodulation therapy that was approved in 1997 for the alleviation of seizures; however, efforts to control epilepsy by stimulating the vagus nerve have been studied for over 100 years. Although its exact mechanism is still under investigation, VNS is thought to affect various brain areas. Hence, VNS has a wide indication for various intractable epileptic syndromes and epilepsy-related comorbidities. Moreover, recent studies have shown anti-inflammatory effects of VNS, and the indication is expanding beyond epilepsy to rheumatoid arthritis, chronic headaches, and depression. VNS yields a more than 50% reduction in seizures in approximately 60% of recipients, with an increase in reduction rates as the follow-up duration increases. The complication rate of VNS is 3–6%, and infection is the most important complication to consider. However, revision surgery was reported to be feasible and safe with appropriate measures. Recently, noninvasive VNS (nVNS) has been introduced, which can be performed transcutaneously without implantation surgery. Although more clinical trials are being conducted, nVNS can reduce the risk of infection and subsequent device failure. In conclusion, VNS has been demonstrated to be beneficial and effective in the treatment of epilepsy and various diseases, and more development is expected in the future.

Key Words: Vagus nerve stimulation ∙ Epilepsy ∙ Neuromodulation ∙ Drug resistant epilepsy ∙ Transcutaneous electric nerve stimulation.

INTRODUCTION

Epilepsy is a major chronic neurological disease affecting many patients, and approximately 68 million people currently live with epilepsy worldwide. A report in 2013 in Korea showed that the prevalence of epilepsy was 2.28 per 1000 people, which corresponded to approximately 115000 patients nationwide. Medical treatment is the first-line therapy for epilepsy. Nevertheless, 30% of patients with epilepsy remain unaffected by medications. Despite the introduction of several new seizure medications in the past 20 years, the proportion of medically intractable epilepsy cases has not changed much. In a recent longitudinal observational cohort study, the overall 1-year seizure-free rate of newly diagnosed epilepsy patients treated with seizure medication was 64%. For those with medically intractable epilepsy, surgical intervention or a ketogenic diet can be a second-line treatment option.

Vagus nerve stimulation (VNS) is an adjunctive neuromod-
Vagus nerve stimulation therapy that was approved in 1997 by the United States of America Food and Drug Administration (FDA) as a palliative treatment for patients with intractable focal seizures. The Korean FDA approved VNS in 1999, and the National Health Insurance Service of Korea decided to reimburse the medical cost for patients who were not candidates for curative resection in 2005. By 2018, VNS devices were implanted into more than 100000 patients worldwide. This is probably not only because VNS yields relatively good clinical outcome but also because it is not a demanding procedure for both patients and neurosurgeons. With innovative devices and wider disease application, the future use of VNS will not be fixed on current indications. This review describes the history, proposed mechanism, clinical outcome, and future implications of VNS as a promising neuromodulation treatment.

HISTORY

Epilepsy has been present in human history, with the first record found in a Babylonian text written 3000 years ago. In the late 18th century, venous hyperemia was suggested as a cause of seizures on the basis of facial flushing and bounding carotid artery pulses during seizures. In the 1880s, New York neurologist James Leonard Corning developed instruments to decrease cerebral blood flow and electronically stimulated the human vagus nerve to abort seizures. However, contemporaries did not widely accept the use of his instruments due to side effects such as bradycardia, dizziness, and syncope. In the 1900s, animal experiments were continuously carried out to uncover the projections and functions of the vagus nerve. Bailey and Bremer reported an increased amplitude and frequency of the frontal lobe after direct stimulation of the vagus nerves of cats in 1938. Similarly, in 1949, MacLean et al. stimulated the vagus nerves of monkeys and found inconsistent slow waves from the frontal cortex. In 1951, Dell et al. reported that the stimulation of vagus nerves affected the rhinal sulcus and amygdala in awake cats. Based on these studies, experiments to elucidate the effects and applications of VNS were conducted. Consequently, Zabara stimulated the cervical vagus nerve of dogs with induced seizures and demonstrated an anticonvulsive effect of VNS. Since VNS had emerged as a promising treatment option for epilepsy, Cyberonics Inc. (Houston, TX, USA) was founded and developed a VNS device with a generator, modeled after a cardiac pacemaker in 1987. By 1988, the first pilot study on VNS implantation in humans for the treatment of epilepsy was carried out in four patients; two patients reported complete seizure control, one reported a 40% seizure frequency reduction, and one reported no effect.

ANATOMY AND MECHANISM

Vagus means ‘wandering’ in Latin, and the vagus nerve got its name for its complex course throughout the body. The vagus nerve is the longest cranial nerve in the body and has the most complex functions. The vagus nerve consists of 80% afferent and 20% efferent fibers. The vagus nerve exits the ventrolateral medulla, crosses the subarachnoid space and enters the jugular foramen to the exit cranium. Vagus nerve fibers can be categorized into four categories on the basis of function and tract-specialized visceral efferent fibers, general visceral efferent fibers, somatic afferent fibers, and visceral afferent fibers. Special visceral efferent fibers from the nucleus ambiguus control the muscles of the palate, pharynx and upper esophagus. The recurrent laryngeal nerve controls the intrinsic laryngeal muscle, except the cricothyroid, whereas the superior laryngeal nerve innervates the inferior constrictor and cricothyroid muscles. General visceral efferent fibers arise from the dorsal motor nucleus and synapses in ganglia within their target organs, such as the heart, lungs and digestive tract, providing parasympathetic innervation. Somatic afferent fibers carry sensations from the pharynx, meninges and region around the external auditory meatus. These fibers enter either the jugular (auricular branch, fibers from the meninges of the posterior fossa) or nodose (fibers from the larynx and pharynx) ganglia and then synapse within the spinal trigeminal nucleus. Visceral afferent fibers carry information from chemoreceptors and baroreceptors of the aortic arch, cardiorespiratory system and digestive system and enter nodose ganglion. These afferent fibers are then integrated at the nucleus of the solitary tract (NTS), where various projections to other regions of the brain occur. The NTS, located in the dorsomedial medulla, is a structure containing a number of neurons that are scattered in the fi-
brillar plexus\(^\text{70}\). It is a transfer center from the brainstem to the cortex, integrating inputs from the vagus nerve, facial nerve, and glossopharyngeal nerve, and has reciprocal projections to various areas of the central nervous system. These include the hypothalamus, rostral ventrolateral medulla, raphe nuclei, A5 nuclei, area postrema, locus coeruleus, amygdala, thalamus and finally the brain cortex\(^\text{31}\). Because of its numerous projections, in addition to the unidentified functions of various nuclei tracts in the human brain, the exact mechanism of VNS is still under investigation.

One of the early efforts to reveal the mechanism of VNS was to find a change in electroencephalography (EEG) activity. However, EEG did not show significant changes in background activity. In contrast, other studies found increased somatosensory evoked potential inter-peak latency, which suggested that VNS affects more than the vagus nerve\(^\text{32,33,74}\). Cerebral blood flow (CBF) changes were measured and showed various results. Although measurements differed in detail throughout studies, VNS induced measurable changes in CBF along the vagus nerve pathways. One study showed CBF changes in the ipsilateral anterior thalamus and cingulate gyrus using positron emission tomography (PET) with \(\text{H}_2\text{15O}\)\(^\text{77}\). Another study reported that decreased CBF in the fusiform gyrus correlated with a seizure reduction\(^\text{35}\). In addition, correlations between bilateral thalamic hyperperfusion and decreased seizure frequency were also reported\(^\text{35}\).

Neurochemical studies were also performed under the hypothesis that VNS might stimulate the release of neurotransmitters throughout the projection sites of vagus nerves. Pioneering studies first revealed an increase in the metabolites serotonin and dopamine and increased gamma-aminobutyric acid (GABA) and ethanolamine levels in the cerebrospinal fluid of VNS patients\(^\text{40,34}\). It should be noted that the raphe nucleus is a major source of serotonergic neurons, whereas the locus coeruleus and A5 nuclei are sources of noradrenergic neurons, and an increase in brain serotonin levels has an antiepileptic effect\(^\text{68}\). In addition, an increase in GABA transmission in rat NTs showed a reduction in susceptibility to limbic motor seizures\(^\text{57}\). VNS significantly increased the hippocampal noradrenalin concentration, and a strong positive correlation was found between noradrenergic and anticonvulsive effects\(^\text{60}\).

Recently, inflammation has been newly identified as one of the causes of epilepsy\(^\text{76}\). Hence, the role of VNS in the inflammatory pathway has become of interest. Numerous papers have reported the vagus nerve in relation to the immune system, but the effect of VNS in epilepsy has not yet been elucidated\(^\text{32,40,74}\). Since the vagus nerve has ‘wandering’ and complicated pathways and effects, the exact role of VNS in epilepsy is inconclusive despite its long history of investigation. Future studies are needed.

**Surgical Procedure**

Under general anesthesia, the patient is arranged in a supine position on the operation bed with horse-shoe headrest or donut-shaped pillow. The neck and upper body should be slightly extended and kept higher than the heart to maintain venous drainage. A VNS device is generally implanted on the left side since the right vagus nerve innervates the sinoatrial node, which leads to an increased risk of cardiac complications. The left arm is abducted approximately 80 degrees to expose the lateral aspect of the chest and axilla. After appropriate skin preparation and draping, a 3–4 cm transverse skin incision is made at the skin crease approximately two finger distances above the clavicle between the medial border of the sternocleidomastoid muscle (SCM) and the midline. Blunt dissection along the SCM muscle is made after dividing the platysma fascia until the carotid sheath is identified. Occasionally sensing the pulsation of the carotid artery can help maintain orientation and lowers the risk of unnecessary injury. The vagus nerve can be gently located after opening the carotid sheath. The vagus nerve is usually located slightly behind the common carotid artery and jugular vein, but the configuration can be variable. Using a microscope or surgical loupe is helpful during this procedure. The vagus nerve is carefully dissected from surrounding structures using microforceps to handle the perineurium sheath to avoid direct injury to the vasa nervorum and vagus nerve itself. The vagus nerve is exposed to approximately 4 cm, and the helical coils are wrapped around the vagus nerve (Fig. 1A). Many surgeons start at the tethering (lower) anchor, then progress to the positive (middle) node and the negative (upper) electrode, but it depends on the surgeon’s preference (Fig. 1B). It is important to ensure that the placement of the electrodes is inferior to the cardiac branches of the vagus nerve to avoid cardiac side effects\(^\text{40}\). Two loops should be made from the lead, one at the proximal
end and one at the distal end for tension release, and the lead should be anchored to nearest fascia or SCM muscle using head holders. Then, a subcutaneous pocket is created at the left thorax. We preferably make an incision inferomedial to axilla and lateral to the pectoralis muscle for cosmetic reasons. In addition, compared with a subpectoral incision, a para-axillary incision is not associated with a higher infection rate. An approximately 5 cm vertical incision is made, and then blunt dissection through the subcutaneous fat on the suprapectoralis muscle is performed. Subcutaneous tunneling is performed from the thorax to the cervix, the lead and battery is connected, and the battery is placed inside the pocket. Attention is required for children or lean persons who have a thin subcutaneous layer because the device may protrude prominently and cause cosmetic disfigurement or even skin erosion. In our institution, we have lowered such side effects by leaving enough of a fat layer over the generator and by changing the device to a model 103 Demipulse® Generator (Cyberonics Inc., Houston, TX, USA), which is smaller than older models. The battery should be checked before placing to be sure it works properly. An anesthesiologist should be advised when checking the function and prepared for adverse cardiac effects. The battery should also be anchored to the pectoralis muscle. The surgery is completed with closing layer by layer.

**CLINICAL OUTCOMES**

The first two single-blinded pilot studies of 14 patients with refractory focal seizures reported mean reductions of 47% and ≥50% in seizure frequency in five patients (36%) after 14 to 35 months of VNS. When the differences between high stimulation and low stimulation were compared, randomized controlled trials showed an approximate 30% reduction in seizure frequency in patients receiving high stimulation (presumed therapeutic dose) and an approximate 15% reduction in seizure frequency in the low stimulation group (presumed subtherapeutic dose). A recent summary of several analyses showed that approximately 60% of patients achieved a ≥50% seizure reduction.

VNS therapy is officially approved for patients over the age of 12 years in the USA and many other countries, and the efficacy and safety of VNS has also been proved in children, showing similar outcomes compared to adults. Reports showed a mean reduction of 71% in seizure frequency at the 3-year follow-up (mean age, 11.5 years) and 54% of patients responded with a ≥50% seizure frequency reduction. Elliot et al. analyzed 141 children, 61% of whom were under 12 years old, and reported the long-term outcome as a mean reduction rate of 76% 10 years after implantation. Long-term outcomes showed that as the follow-up duration increases, the
An analysis of VNS in children under the age of three reported that 33% of patients improved their seizure frequency without significant adverse effects compared to adults. The study also found that negative (normal) magnetic resonance imaging (MRI) was associated with seizure improvement, and VNS reduced the frequency of status epilepticus. Considering the adverse effects, such as cognitive and psychological dysfunction, of prolonged seizure medications initiated at childhood, early VNS for drug refractory epilepsy is a viable option. However, protrusion of the device and skin problems may be impediments at very young ages.

VNS is a promising option for pregnant women with medically refractory seizures with no report of teratogenic effects. In addition, a recent study revealed that VNS devices implanted in intractable epilepsy patients resulted in a lower rate of sudden unexpected death in epilepsy (SUDEP) by a rate ratio of 0.68 compared to rates in non-implanted patients.

An analysis regarding Asian ethnicity showed no difference. A 4-year follow-up after VNS showed a 60% rate of ≥50% seizure frequency reduction in a Korean study (mean age, 22.3 years; range, 8–44 years). Chinese colleagues retrospectively analyzed the effects of VNS on children (range, 1–14 years) and showed a 57.2% of patients experienced a ≥50% seizure frequency reduction. A Japanese prospective study revealed a median seizure reduction of 66.2% after 3 years of VNS.

A meta-analysis of VNS studies including 74 clinical studies, 3321 patients showed seizure frequency reduction of 51% after 1 year of therapy. The analysis also found that children experience better outcome than adults. Greatest benefit was related to posttraumatic epilepsy with 79% reduction in seizure, and tuberous sclerosis with 68% reduction in seizures. In addition, generalized epilepsy had higher reduction rate than focal seizures, by 58% to 43%.

**APPLICATIONS BEYOND EPILEPSY**

VNS has shown various other effects, including improvements in alertness, attention and psychomotor activity. VNS has been approved for treatment-resistant depression patients ≥18 years old with at least one major depressive episode defined by the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). Although VNS has not been developed for use in depression, significant mood improvements were observed, which were independent of effects on seizure activity. Two-year outcomes of VNS for the treatment of refractory depression showed that 53% of patients had a ≥50% reduction in the Hamilton Rating Scale for Depression (HRSD28) scores from baseline. Similar results were conducted in children who were treated VNS for epilepsy, showing a tendency of improvement in mood scale questionnaire scores. Although more research is needed, VNS could be an effective option for pediatric depression.

Recently, VNS studies for cluster headaches and migraines showed favorable outcomes. Silberstein et al. conducted a randomized double-blind clinical trial of noninvasive VNS in episodic cluster headache patients and found a response rate of 27% in VNS-treated subjects compared to 15% in sham-treated subjects. Similarly, migraine patients with noninvasive VNS achieved pain reduction of 56% at 1 hour and 65% at 2 hours with a ≥50% reduction in visual analog scale (VAS) scores. Since many patients suffering from cluster or migraine headaches complain of unsatisfactory drug response, stimulating VNS can be helpful.

Notably, VNS has anti-inflammatory properties, and VNS has shown success in treating inflammatory disorders such as rheumatoid arthritis, diabetes, sepsis and cardiovascular disorders.
One interesting study revealed that VNS inhibited inflammatory cytokine, including tumor necrosis factor (TNF) and interleukin (IL)-6, production in RA, as 57% of RA patients with active disease, despite methotrexate therapy, showed a ≥50% improvement43). However, the roles of VNS in various psychiatric and functional diseases are still under investigation and development. Additional studies are mandatory to investigate its mechanism of action and application to various diseases.

SAFETY AND COMPLICATIONS

The vagus nerve is composed of three fibers, A, B, and C, according to conduction velocity. A fibers are myelinated fibers that have the largest diameter and carry visceral afferent and motor input information. B fibers are myelinated fibers with small diameters that carry parasympathetic input information. C fibers are unmyelinated fibers with small diameters that carry visceral afferent information. Fortunately, investigators have found that within human VNS parameters, only A and B fibers are activated due to lower activation thresholds. The activation of C fibers may have unwanted side effects, such as involvement in the cardiopulmonary system, which are not observed in most patients19).

The most common acute side effects of VNS are infection, vocal cord paresis, and lower facial nerve palsy. Cardiac-related side effects, such as bradycardia and asystole, mainly occurred during device testing but have rarely occurred after initiation2,72). Vocal cord paresis and lower facial palsy have become rare due to improved surgical techniques56). For long-term use, the most common side effects were stimuli-related cough, throat pain, and hoarseness, all of which tend to improve over time9). Compared with adults, children did not show meaningful differences9).

Since other complications are rare or transient, postoperative infection is the most serious complication to consider. Postoperative infection occurs in 3–6% of patients8). Despite some reports suggesting that oral antibiotics are sufficient for treatment8, many institutions consider surgical removal of all devices mandatory27,60). Especially in cases of infection in deep tissue layers, all devices must be removed20). This idea fits with our experience in which oral antibiotics were effective only for minor superficial skin infections, and in cases of infections below the skin level, removing devices with intravenous antibiotics was the only effective control for the infection. Studies have reported that revision surgery is feasible and safe31). Hence, removing the device should be the first option to consider in cases of overt deep-layer infection.

VNS is generally implanted on the left side. An early VNS experiment was performed in dogs, but the cervical anatomy of humans is much more complicated than that in dogs62). In fact, the cervical vagal trunk where the VNS electrodes are normally placed in humans does not have superior or inferior cardiac branches, thereby minimizing clinically relevant cardiac side effects regardless of the side of implantation44). There are case reports that right-sided VNS implantation did not show cardiac side effects31,70). Thus, right-sided VNS is a considerable option if the left side approach is difficult due to various reasons, such as prior infection on the left side.

NONINVASIVE VNS

Recently, noninvasive VNS (nVNS) has become a new topic. nVNS does not require implantation surgery and stimulation works trans-cutaneously. nVNS involves an intra-auricular electrode (NEMOS, Cerbomed, Erlangen, Germany) or a portable stimulator and digital user interface that controls signal amplitude (gammaCore, electroCore LLC, Basking Ridge, NJ, USA)11). NVNS has an advantage compared to conventional VNS as it does not require surgery, minimizing the risk of infection. Stefan et al.71) stimulated the left auricular branch of the vagus nerve in 10 adult patients, and the seizure frequency was reduced by 45% and 48% in two patients. He et al.36) also investigated the outcome of transcutaneous VNS and showed a mean reduction seizure frequency of 54% at 6 months. NVNS can be a promising therapy for treating intractable epilepsy in the future when additional clinical trials have been completed. Some adverse effects of nVNS have been reported, such as oropharyngeal pain or neck pain28).

CONCLUSION

VNS is an effective neuromodulation that controls intractable epilepsy and has a long history of use. Although the exact mechanism is still under investigation, the outcome of VNS is
shown to be favorable with few adverse effects, based on clinical evidence. Furthermore, VNS is applicable to various other diseases, such as depression and chronic pain, brightening the future of neuromodulation therapy.

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

INFORMED CONSENT

This type of study does not require informed consent.

References


60. Raedt R, Clinckers R, Mollet L, Vonck K, El Tahry R, Wyckhuys T, et al. : In-
creased hippocampal noradrenaline is a biomarker for efficacy of vagus nerve stimulation in a limbic seizure model. J Neurochem 117 : 461-469, 2011
64. Rosenfeld WE, Roberts DW : Tonic and atonic seizures: what's next--VNS or callosotomy? Epilepsia 50 Suppl B : 25-30, 2009